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Aim: To study antitumor activity of triptorelin — agonist of gonadotropin-releasing hormone and exemestane — inhibitor of aromatase 
in monotherapy and in combination with cisplatin on the model of receptor-positive for estrogens and progesterone malignant ascites 
transplantable ovarian tumor (TOT), to assess therapeutic pathomorphosis and level of VEGF expression in tumor cells using diffe rent 
combinations of cytostatics and hormonal drugs. Materials and methods. 72 female Wistar rats, which underwent intraperitoneal 
transplantation of ascitic TOT, by 5·106 cells per animal, have been involved in the study. Rats were divided into 8 groups, 9 rats in each 
group. Histological study with assessment of therapeutic pathomorphosis in TOT and immunohistochemical study has been carried 
out. Survival of animals in the studied groups has been evaluated. Results. Among animals treated in regimen of monotherapy, the most 
pronounced antiangiogenic activity in TOT has been observed on application of hormonal drugs (triptorelin — 39.4 ± 1.9 and exemes-
tane — 33.9 ± 1.4%; р = 0.003), the highest grade of treatment pathomorphosis in TOT has been observed at treatment with cispla-
tin (11.7%; р = 0.001). Combination of triptorelin and exemestane has amplified antiangiogenic activity in TOT (12.2 ± 0.9%; 
р = 0.001), but has not significantly changed rates of pathomorphosis (22.1 ± 0.4%; р=0.005) and survival of animals (32.2%; 
р = 0.007) as compared with the same rates in rats treated with hormonal drugs in monotherapy. Significant correlation between VEGF 
expression and pathomorphosis has been established (relative part of viable tumor tissue (RPVTT)) in TOT (r = 0.712; р = 0.001), 
as well as between RPVTT and life-span of animals (r = −0.320; р = 0.007). However, lack of correlation between VEGF expression 
in cells of TOT and survival of rats has been determined (r = −0.194; р = 0.11). Combination of cytostatic agent with triptorelin 
or exemestane has demonstrated significantly high rates of therapeutic pathomorphosis (10.1 ± 0.1% and 16.2 ± 0.3%, respectively) 
and antiangiogenic activity in TOT (21.4 ± 1.4% and 15.0 ± 1.3%, respectively) as well as the highest survival of animals (100.0%, 
increase of life-span (ILS) = 231.9% and 85.7%, ILS = 205.8%, respectively) as compared with the same one in rats treated 
in regimen of monotherapy with cisplatin, triptorelin, exemestane or by combination of hormonal drugs. Among animals treated 
by combination of cytostatic drug with triptorelin, two were cured, and among rats, which received cisplatin and exemestane, one 
animal was cured. Conclusions. Triptorelin and exemestane increase antitumor activity of cisplatin in respect to the malignant ascitic 
TOT and significantly increase survival of animals, especially when triptorelin and cisplatin are used in combination.
Key Words: ascites transplantable ovarian tumor, rat, cytostatic, agonist of gonadotropin-releasing hormone triptorelin, inhibitor 
of aromatase exemestane, pathomorphosis, VEGF, survival.
INTRODUCTION
The main reason of ineffectiveness of numerous ef-
forts to improve the results of treatment of patients with 
ovarian cancer (OC) lies in the late diagnostics. Lack 
of pathognomic symptoms for the early stages of disease 
complicates this task. The principal difficulty consists 
in the fact that there is no scientifically substantiated 
understanding of pathogenesis of OC till present time. 
The understanding of OC pathogenesis would solve the 
problem of early diagnostics and opportunity to carry out 
more effective treatment. Late diagnostics, in turn, and 
aggressive clinical course of OC, as well as wide variety 
of histogenetic variants, complicate the study of patho-
genesis. However, till present time, significant amount 
of experimental, epidemiological and clinical facts have 
been accumulated, which have shown that the leading 
role in OC pathogenesis is played by the interaction be-
tween complicated mechanisms of endocrine-metabolic 
and molecular-genetic disorders [1–4].
Hormone-dependence of OC is demonstrated 
by the results of different studies, which have determined 
that ovaries are not only producing sex steroid hormones, 
but also are tissue-target for gonadotropin classical and 
nonclassical steroid hormones, as well as gonadotropin-
releasing hormone [5, 6]. Moreover, OC is characterized 
by the pronounced heterogeneity of molecular-biological 
markers of tumor cells and their complicated interac-
tions with environmental factors that in combination 
form significantly variable tumor phenotype [7–9]. It has 
been proved that OC has high frequency of positive 
expression of all steroid hormone receptors [10–12]. 
Upon the impact of the last ones, rate of particular pro-
teins synthesis in target-cells changes that causes the 
modulation of cellular signal pathways, change of meta-
bolic processes in the cell and, finally, determines the 
capability of its proliferation, differentiation, apoptosis, 
adhesion and angiogenesis [2]. Interaction between 
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steroid hormones and many other molecular markers 
with tumor cell receptors as well as the mechanisms for 
receptor signals implementation in the cellular nucleus 
are insufficiently studied at breast cancer (BC) [13–15]. 
Nowadays, standard diagnostic and therapeutic criteria 
of hormonal, cytotoxic and target therapy have been 
determined for this disease [16, 17].
Strategy of treatment of OC patients includes 
surgical component and chemotherapy. Despite 
the improvement of surgical treatment strategies and 
application of modern schemes of chemotherapy [17–
21], remote results of treatment of patients with dis-
seminated OC remain unsatisfactory [22]. The matter 
of hormonal therapy application in this category of pa-
tients remains discussable today. Over many years, 
hormonal treatment has been prescribed empirically 
as “therapy of despair” for the patients with chemore-
sistant and relapsing OC, when the other therapeutic 
methods have sputtered themselves out having low 
index of effectiveness [3, 5]. National USA standards 
recommend prescription of agonists of gonadotropin-
releasing hormone (aGn-RH) and inhibitors of aroma-
tase for the patients with chemoresistant and relapsing 
OC as well as debilitated patients [23].
Many studies on OC show that estrogens and andro-
gens cause proliferation of ovarian tumor cells in vivo 
and in vitro [24, 25]. Moreover, some authors have de-
termined that positive hormonal receptor status of OC, 
in particular strong expression of estrogen receptors 
(ER) and vascular endothelial growth factor (VEGF) 
are the factors of unfavorable clinical outcome [11, 
26–29]. Nowadays, it has been proved that estradiol 
induces expression of VEGF and its receptors via ER-
signal pathways in the cells of reproductive system 
organs at physiological and tumor angiogenesis [30]. 
Results of some studies have shown anti-proliferative 
and apoptotic effect of aGn-RH in ovarian tumor cells 
in vivo and in vitro [31]. Moreover, some authors have 
observed decrease of the level of VEGF and ER ex-
pression at treatment of ER-positive OC with inhibitors 
of aromatase, having noticed decrease of proliferation 
and apoptosis of tumor cells [32]. However, there are 
also contradictory scientific data [33–35].
Since no full understanding of mechanisms of re-
alization of hormone-receptor signal in ovarian tumor 
cells, which launch cascade processes of proliferation, 
invasion and metastasis has been obtained, specifi-
cation of these mechanisms will have significance for 
the substantiation of indication to hormonal therapy 
not at relapses of OC, but as a component of the pri-
mary complex treatment of patients.
Aim of study — to investigate antitumor activity 
of aGn-RH — triptorelin and inhibitor of aromatase — 
exemestane in monotherapy and in combination with 
cytostatic cisplatin on the model of receptor-positive 
for the estrogens and progesterone malignant asci-
tes transplantable ovarian tumor (TOT), to evaluate 
pathomorphosis and expression of VEGF in tumor 
cells using different combinations of cytostatic and 
hormonal drugs.
MATERIALS AND METHODS
Animals. 72 female Wistar rats (130–150 g b.w.) 
bred in the vivarium of the R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobio-
logy, NAS of Ukraine (Kyiv, Ukraine) have been involved 
in the experiment. All care procedures have been 
provided in accordance with the recommendations 
for conducting the medical-biological studies with use 
of laboratory animals.
Tumor. Strain of TOT created in 1958 through the trans-
plantation of ovarian tumor from rat, which underwent dia-
placental impact of 7.12-dimethylbenz(a)anthracene, has 
been used. Strain of TOT was obtained from N.N. Blokhin 
Cancer Research Center (RAMS, Moscow, Russia). 
After preliminary passage on the 9th day, after intra-
peritoneal transplantation of TOT, ascitic liquid was taken 
from one rat and transplanted to 72 rats intraperitoneally 
by 0.5 ml, diluted with physiological solution and conta-
ining by 5•106 cells per animal. Transplantable ascitic 
liquid was immunocytochemically tested for the deter-
mination of expression of steroid hormone receptors.
Immunocytochemical test (ICC) has been 
carried out using monoclonal antibodies specific 
to the ER — anti-Rat Estrogen Receptor alfa (Clone 
6F11, Thermo Scientific, USA), progesterone recep-
tor (PR) — anti-Rat Progesterone Receptor (Clone 
PR-AT 4.14, Thermo Scientific, USA). For visualization 
of the results of reaction, Poly Vue system (Thermo Sci-
entific, USA) conjugated with peroxidase has been ap-
plied and activity of enzyme has been developed using 
3,3-diaminobenzidine as a substrate (Thermo Scien-
tific, USA). After ICC reaction, specimens were stained 
with Mayer hematoxylin (Sigma, USA). For evaluation 
of ICC expression of ERs and PRs, semi-quantitative 
method was applied. When specific nuclear staining 
for steroid receptors was present, number of immune-
positive and immune-negative cells was determined 
in percentage. Expression of steroid receptors per 
1000 tumor cells has been defined in each cytological 
specimen. For the total assessment of ERs, PRs ex-
pression in TOT, method applied by us earlier [10] has 
been used. Grade of expression of steroid receptors 
was represented in scores: 0 score — lack of staining 
of tumor cell nuclei; 1 score — poor staining, ≤ 10%; 
2 scores — moderate grade, 11–50%; 3 scores — high 
grade, 51–80%; 4 scores — hyperexpression, > 81% 
of cells. Quantity of stained nuclei of tumor cells more 
than 10% with moderate and high grade of staining 
was taken as positive expression of steroid receptors.
Therapy. Cisplatin has been used as solution for 
injection (0.5 mg/ml in 100 ml). Triptorelin was used 
in the form of dry substance of triptorelin acetate 
0.1 mg+ mannite 10 mg and solvent in the form of so-
dium chloride 0.9% 1 ml. Exemestane was applied 
in the form of pills, 1 pill contains 25 mg of exemestane.
Treatment with exemestane was started in the day 
of transplantation and has been carried out during 
10 days, with cisplatin and triptorelin — 48 hours after 
transplantation during 5 days. Therapeutic drugs were 
applied to animals in therapeutic doses according 
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to the current method recommendations and data 
of previously conducted studies [36–40].
Rats were divided into 8 groups, 9 rats in each 
group (Table 1).
Table 1. Groups of animals according to treatment regimen 
Animals, n = 72 Treatment
Group 1 (С), n = 9 Physiological solution intraperitoneally 0.5 ml du-
ring 5 days and orally 0.5 ml for 10 days
Group 2 (Р), n = 9 Cisplatin intraperitoneally 1.0 mg/kg — 0.15 mg/
rat/per day or 0.3 ml + 0.3 ml of physiological so-
lution/rat/per day during 5 days
Group 3 (Т), n = 9 Triptorelin intramuscularly 0.1 mg/rat/per day for 
5 days
Group 4 (Е), n = 9 Exemestane orally 12.5 mg + 0.5 ml physiological 
solution/rat/per day during 10 days
Group 5 (Р + Т), 
n = 9
Combination of cisplatin and triptorelin in men-
tioned above doses for 5 days
Group 6 (Р + Е), 
n = 9
Combination of cisplatin and exemestane in men-
tioned above doses
Group 7 (Р + Т + Е), 
n = 9
Combination of cisplatin, triptorelin and exemes-
tane
Group 8 (Т + Е), 
n = 9
Combination of triptorelin and exemestane
Observation has been started in 24 hours after 
the last injection of exemestane. Died or euthanized 
animals underwent autopsy for macroscopic evalu-
ation of dissemination of tumor process and patho-
logical changes of internal organs. Cancer-changed 
organs of peritoneal cavity and pelvis of rats were 
removed for histological and immunohistochemical 
studies. In order to evaluate dynamics of tumor process 
objectively, studied animals were euthanized by one rat 
from each group on 14th, 17th and 19th day of observa-
tion. Moreover, macroscopic study of internal organs 
in intact rats was carried out for the objective analysis 
of pathological changes in organs of peritoneal cavity 
and pelvis of the studied animals.
We judged about antitumor effectiveness of treat-
ment drugs by survival of animals, morphological 
assessment of treatment pathomorphosis (RPVTT) 
and the level of expression of VEGF in TOT. Rats’ life 
span was evaluated by a mean of life-span (MLS) and 
an increase of life-span (ILS) as compared with control. 
ILS in percentage was calculated by formula:
  MLS0 — MLSr ILS = ———————————— × 100%, 
  MLSr
where MLS0 and MLSr — mean of life-span rat’s of trial 
and control groups, respectively.
Histological analysis. Obtained material was fixed 
in buffered 10% formalin with pH 7.4 and condensed 
in paraffin using histoprocessor Histos-5 (Milestone, 
Italy). From paraffin blocks, histological sections 5 mic 
thickness were prepared with the help of microtome 
Microm HM325 (Thermo Scientific, Germany). Sec-
tions were stained with hematoxylin-eosin. Analysis 
of pathomorphosis in tumor tissues was carried out 
according to K.A. Galakhin [41] determining a relative 
part of viable tumor tissue (RPVTT) in percentage.
Immunohistochemical analysis (IHC) has been 
carried out, with use of monoclonal rat antibody specific 
to VEGF — anti-VEGF Ab-1 RB-222 Polyclonal (Thermo 
Scientific, USA) as presented early [28]. For visualiza-
tion of the results of reaction, kit of reagents EnVision 
system (DakoCytomation, Denmark) was used accord-
ing to the recommendations of manufacturer. Sections 
were stained with Mayer hematoxylin. Grade of VEGF 
expression was evaluated in scores: 0 score — lack 
of staining of cytoplasm and membrane of tumor cells; 
1 score — poor staining, 1–25% of tumor cells (VEGF+); 
2 scores — moderate grade of proportional staining, 
26–50% of tumor cells (VEGF++); 3 scores — high grade 
of staining or hyperexpression, more than 50% of tumor 
cells (VEGF+++) [17]. As positive expression of VEGF 
(VEGF+) was taken more than 25% of tumor cells with 
moderate and high immunohistochemical expression. 
As positive control, monoclonal antibodies against 
pan-cytokeratines were applied, as negative control — 
buffered physio logical solution, which was placed onto 
histological sections instead of monoclonal antibodies.
Obtained results were studied and photographed 
using microscope Nikon Eclipse 80i with camera DS-
5SMc/L2 and optical magnification ×400.
Toxic effect of antitumor drugs has been assessed 
by control of spleen weight and by macroscopic study 
of pathological changes in liver and kidneys of animals.
Statistical analysis. Processing of the results 
of study has been carried out using program package 
STATISTICA 6.0. Parametric statistics including method 
of Student’s t-criterion was used. Correlation has been 
assessed using Pearson pair correlations. Survival 
of animals has been analyzed by Kaplan — Meier, log-
rank criterion was used for paired comparisons, crite-
rion χ2 — for multiple comparisons between groups. 
Data were considered statistically significant at р < 0.05.
RESULTS AND DISCUSSION
In this article, we will analyze results of study of con-
trol animals and rats with TOT of 2–4 groups.
In accordance with IHC study, grade of expression 
of ERs and PRs in ovarian tumor cells was high — 60% 
each.
In all animals, which were administered suspension 
of cells of TOT and which received physiological solution 
(Group 1, C), strong hemorrhagic ascites was observed 
(volume of ascitic liquid 18 ± 2.5 ml). Macroscopically, 
significant tumor changes of parietal and visceral perito-
neum, organs of peritoneal cavity and pelvis with invasion 
of omentum were observed in all rats. Many animals had 
tumor-like excrescences in serous tissue of intestine. 
Everting papillary tumor, which 2–5 times exceeded 
dimensions of normal ovaries of intact rats, with dis-
semination in corpus uteri and uterine tubes has been 
discovered in ovaries. Some animals had tumor in anterior 
abdominal wall. At macroscopic assessment of spleen, 
liver and kidneys, no significant pathologic changes 
were determined. Spleen weight was 1119.4 ± 10.1 mg. 
Histologically, excrescences of adenocarcinoma with 
broad necrosis, angiomatosis, hemorrhages (Fig. 1) 
were observed in ovaries and omentum. In most of rats, 
carcinomatosis of uterus, uterine tubes, mesentery and 
serous tissue of intestine was observed, in peritoneal 
wall — single metastases grown through the muscles. 
Viable parts of tumor are represented in some focuses 
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by quite large cells with big, moderately dense nuclei 
and cytoplasm of diffe rent grade of basophilia, and, 
in the other — cells with vacuo les in cytoplasm prevailed, 
which number significantly varied. RPVTT constituted 
50.1 ± 4.7% in average (see Fig. 1; Table 2). At IHC study, 
irregular expression of VEGF in cells of TOT was deter-
mined (see Fig. 1). In parts of tumor consisting of cells 
with dense basophilic cytoplasm, high expression of VEGF 
(3+) was observed, among the vacuolated cells — mode-
rate grade of expression of this marker, and in parts 
of degeneration — low. However, on the whole, grade 
of expression of VEGF in TOT of rats of the control group 
was high (77.8 ± 8.3%) (see Fig. 1, Table 2). MLS was 
13.7 ± 1.5 days. Since maximal lifespan of rats of the con-
trol group was 20 days, in order to compare survival 
of animals from the other groups in respect to the control 
group, 20 days were taken as final point of observation 
interval. For rats of the 1st group, 20-day survival was 
17.6% (1 rat), MLS — 13.7 ± 1.5 days (Table 3, Fig. 2, 3). 
Thus, represented model of TOT is characterized by ag-
gressive clinical course of tumor process.
In animals, which received cisplatin (Group 2, P), 
less pronounced hemorrhagic ascites was observed 
as compared with rats of the control group (volume 
of ascitic liquid was 12.9 ± 5.8 ml). Dissemination of tu-
mor process in organs of peritoneal cavity and pelvis 
in rats of this group did not differ from the same one 
as compared with control animals, but grade of invasion, 
number of tumor focuses and their dimensions were 
significantly lesser. In some animals, lysis of omentum 
was observed. In one rat, euthanized on day 17, there 
was no ascites and apparent involvement of peritoneal 
cavity, but ovaries were enlarged with everting papillary 
tumor. Insignificant icteritiousness of liver and kidneys 
was detected in two animals. Mean spleen weight was 
decreased by 26.4% (823.9 ± 10.0 mg) and as compared 
with the same one in control animals had significant dif-
ference (р < 0.05). Histologically, excrescences of ade-
nocarcinoma had disseminated necrosis, hemorrhages, 
and strong angiomatosis. Parts with necrosis had abun-
dant leucocytic and lymphocytic infiltration (see Fig. 1). 
In TOT, cells with vacuolated cytoplasm and nuclear 
polymorphism prevailed as well as cells with pyknotic 
nuclei. Sometimes, tumor cells with excrescent forms 
were observed and they looked like mesenchymal cells. 
Mean RPVTT in animals of this group was 11.7 ± 0.6% 
that significantly differed from the same index in control 
rats (p = 0.01). In parts with viable tumor cells, variability 
of VEGF expression was observed, in some cells, high 
expression was noted, in the other — poor expression 
being 58.3 ± 2.6% on average that was significantly lower 
than the same index of TOT in rats of the control group 
(р = 0.01) (see Table 2). As seen from data of Table 3 and 
Fig. 2, 3, survival rates of animals of the second group 
were significantly higher as compared with the same 
ones of control rats (p = 0.016). ILS was 104.4%.
Rats treated with triptorelin (Group 3, T) had volume 
of ascitic liquid 15.7 ± 6.1 ml, which in most animals 
was serous-“lactic”. Distinctive feature of tumor pro-
cess in most of the rats was insignificant “adhesive” 
process, lack of tumor involvement of parietal perito-
neum, peritoneal cavity and pelvis, uterus and uterine 
tubes, atrophy of ovaries with insignificant papillary ex-
crescences. In visual assessment of liver and kidneys, 
no pathological changes were demonstrable, in one 
of the animals moderate icteritiousness and flabbiness 
of liver were noticed. Mean weight of spleen was de-
creased insignificantly by 9.8% (1009.7 ± 10.0 mg) that 
had no significant difference in respect to the same 
one in control animals (р > 0.05).
Histologically, multiple necroses and hemorrhages 
(see Fig. 1) were detected in tumor focuses. Viable 
tumor tissue was represented in the form of islets. 
Cells with vacuolated cytoplasm prevailed in tumor 
tissue, though significant part of cells with proporti o-
nally stained basophilic cytoplasm was observed in it, 
and only small part of them had signs of dystrophic 
changes with pyknotic nuclei. Mean RPVTT constituted 
30.3 ± 0.4% that is significantly lesser as compared 
with the same one rate in rats of the control group 
(р = 0.001) and significantly higher than in animals 
of group 2 (р = 0.01). Angiomatosis in tumor was ob-
served more rarely in contrast to the TOT of animals 
in groups 1 and 2. Moderate grade of expression of VEGF 
in tumor cells was observed (39.4 ± 1.9%) that is signifi-
cantly lower as compared with the same one in TOT cells 
of control group and group 2 (р = 0.001 and р = 0.003, 
respectively) (see Table 2). Survival of rats in this group 
was higher, than in control, and lower, than in animals 
of group 2 (see Table 3, Fig. 2, 3), but statistical analysis 
has determined lack of significant differences between 
rates (р=0.22 and р=0.12, respectively). ILS was 23.4%.
Table 2. Antitumor effectiveness and toxic effect of therapeutic drugs 
in monotherapy by RPVTT, level of VEGF expression in cells of TOT and 
change of spleen weight in rats (n = 36)
Group of animals RPVTT, % VEGF, % Spleen weight decrease, %
Group 1 (K), n=9 50.1 ± 1.6 77.8 ± 2.8 –
Group 2 (P), n=9 11.7 ± 0.2* 58.3 ± 2.6* 26.4*
Group 3 (Т), n=9 30.3 ± 0.4* 39.4 ± 1.9* 9.8
Group 4 (Е), n=9 31.4 ± 0.3* 33.9 ± 1.4* 8.7
Note: *p < 0.05 in comparison with the control group.
Animals treated in monotherapy regimen with 
exe mestane (Group 4, E) had volume of ascitic liq-
uid 13.3 ± 5.3 ml, which in most of them was serous-
“lactic”. The fact was interesting that at macroscopic 
assessment for organs of peritoneal cavity and pelvis 
in 6 rats, which died in earlier terms of observation and 
euthanized on days 14, 17, signs of tumor involvement 
were absent, ovaries were atrophic. In rat, which was 
euthanized on day 19, pronounced tumor process in or-
gans of peritoneal cavity and pelvis was observed, but 
in two animals, which died on day 23 and 24, moderately 
pronounced tumor involvement was observed. Spleen 
weight decreased by 8.7% (1022.0 ± 8.4 mg) that dif-
fered insignificantly from the same one in intact animals 
(р > 0.05), liver and kidneys had no visual pathological 
changes. Histologically, in TOT, the same as in previ-
ous groups, multiple necrosis and hemorrhages, less 
pronounced angiomatosis were observed as compared 
with the same one in TOT of animals in control group and 
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group 2 (see Fig. 1). Significant part of viable tumor cells 
had comparatively large sizes, proportionally stained 
basophilic cytoplasm, large light nuclei. Degenerating 
cells with enlightened cytoplasm and pyknotic nuclei 
were found relatively often. Rates of RPVTT and VEGF 
expression significantly did not differ from the same ones 
in TOT affected by triptorelin (31.4 ± 0.3% and 33.9 ± 1.4, 
respectively), but, at the same time, statistical analysis has 
determined significant differences between these rates 
and the same rates in rats of groups 1 and 2 (p = 0.01) (see 
Table 2). Survival of animals of this group (30.9 ± 13.9%) 
also did not differ significantly from the same one in rats, 
which received monotherapy with triptorelin. It was higher, 
than in control, and lower, than in animals of group 2, but 
differences between rates were insignificant (р = 0.19 and 
р = 0.2, respectively). ILS was 22.6% (see Table 3, 
Fig. 2, 3).
Table 3. Survival rates of rats in groups 1–4 (n = 36)
Group of animals ILS, % MLS, days Min LL, days
Max LL, 
days OS, %
Group 1 (C) n = 9 – 13.7 ± 1.5 6 20 17.6 ± 13.8
Group 2 (P) n = 9 104.4 28.0 ± 4.2* 16 54 54.8 ± 14.8*
Group 3 (Т) n = 9 23.4 16.9 ± 2.1 11 27 37.1 ± 16.3
Group 4 (Е) n = 9 22.6 16.8 ± 1.7 10 24 30.9 ± 13.9
Note: Min LL — minimal length of life; Max LL — maximal length of life; 
OS — 20-day survival; *p < 0.05 in comparison with the control group.
Obtained by us variable histological, IHC rates and 
the results of survival of animals treated with different 
therapeutic drugs in monotherapy served the basis for 
carrying out analysis of correlation between RPVTT 
in TOT, expression of VEGF in cells of tumor with life-
Group 1 (C) H & E, ×100 Group 1 (C) H & E, RPVTT, ×400 Group 1 (C), VEGF, ×400
Group 2 (P) H & E, ×100 Group 2 (P) H & E, RPVTT, ×400 Group 2 (P), VEGF, ×400
Group 3 (Т) H & E, ×100 Group 3 (Т) H & E, RPVTT, ×400 Group 3 (Т), VEGF, ×400
Group 4 (Е) H & E, ×100 Group 4 (Е) H & E, RPVTT, ×400 Group 4 (Е), VEGF, ×400
Fig. 1. Microphotography of transplantable tumor in ovaries of animals in the groups 1–4: Group 1 (C) — rats received physiological 
solution; Group 2 (P) — rats treated with cisplatin; Group 3 (Т) — rats received triptorelin; Group 4 (Е) — rats received exemestane. 
RPVTT — relative part of viable tumor tissue, VEGF — expression of VEGF in tumor cells. H & E — hematoxylin-eosin
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span of rats (Table 4). As seen from Table 4, there 
is an inverse correlation between survival of animals 
and rate of RPVTT in TOT (r = −0.320; р = 0.007), as well 
as direct correlation between RPVTT and expression 
of VEGF in tumor cells (r = 0.712; р = 0.001), no cor-
relation between survival of animals and VEGF in TOT 
expression was detected (r = −0.194; р = 0.11).
Table 4. Correlation coefficients significant at р < 0.05 between life-span 
of rats, expression VEGF and RPVTT in TOT (n = 69)
Index Correlation coefficient р
Life-span (days) & RPVTT −0.320 0.007
Life-span (days) & VEGF −0.194 0.11
RPVTT & VEGF 0.712 0.001
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Fig. 2. Overall survival of rats in all groups. Kaplan — Meier 
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Fig. 3. Overall survival of rats in groups 1–8. *p < 0.05 compared 
to the control group
Thus, represented model of TOT, with positive hor-
monal receptor status and high expression of VEGF, 
had aggressive clinical course that was confirmed 
by macroscopic assessment of dissemination of tumor 
process, histological and IHC studies, as well as survival 
rates of animals. Obtained results have demonstrated 
effectiveness of cytostatic agents and hormonal drugs 
in monotherapy. We have shown that not only cisplatin, 
but also hormonal drugs triptorelin and exemestane 
in monotherapy caused therapeutic pathomorphosis 
in TOT that allows to judge indirectly about antiproli-
ferative and apoptotic activity of these drugs [42–45]. 
However, grade of treatment pathomorphosis in TOT 
under the effect of cisplatin was significantly higher, 
than in monotherapy with triptorelin or exemestane. 
At the same time, hormonal drugs showed significantly 
higher antiangiogenic activity in TOT as compared with 
the same one in monotherapy with cytostatic drugs. 
Survival of rats, which received monotherapy with trip-
torelin or exemestane, was higher, than in the control 
group and lower, than in animals treated with cisplatin, 
but differences between rates had no significance. 
Represented results are confirmed by lack of correlation 
between VEGF expression in cells of TOT and survival 
of animals. At the same time, significant correlation be-
tween VEGF expression and treatment pathomorphosis 
(RPVTT) in TOT, as well as between RPVTT and life-
span of rats has been determined. Moreover, we have 
observed that hormonal drugs had no significant toxic 
effect as compared with cisplatin.
CONCLUSIONS
In animals with TOT, which received monotherapy 
with cisplatin, triptorelin or exemestane, most pro-
nounced angiogenic activity in tumor was observed 
with use of hormonal drugs. However, the highest 
grade of treatment pathomorphosis in TOT was ob-
served at treatment with cisplatin. Significant cor-
relation between expression of VEGF and treatment 
pathomorphosis (RPVTT) in TOT, as well as between 
RPVTT and life-span of animals, has been determined. 
 However, lack of correlation between expression 
of VEGF in cells of TOT and survival of rats was observed.
Hormonal drugs have no significant toxic effect 
as compared with cisplatin.
Survival of rats treated with monotherapy using 
triptorelin or exemestane was higher than in the control 
group and lower than in animals, which received cispla-
tin, but differences between rates were not significant.
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